Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost
DalCor Raises $80m For Dalcetrapib Confirmatory Trial
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
